Morgan Stanley lowered the firm’s price target on Crispr Therapeutics (CRSP) to $30 from $45 and keeps an Underweight rating on the shares. The ...
In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...
Fintel on MSN16h
Morgan Stanley Downgrades Intellia Therapeutics (NTLA)Fintel reports that on January 27, 2025, Morgan Stanley downgraded their outlook for Intellia Therapeutics (NasdaqGM:NTLA) ...
Visualizing cells after editing specific genes can help scientists learn new details about the function of those genes. But ...
With an estimated 1.5 lakh cases of oral cancer diagnosed annually in India and a high mortality rate due to late detection, ...
Researchers can easily track and isolate bit.bio's consistent, defined, and scalable human iPSC-derived cells for the first time, opening up new applications in neurodegenerative drug discovery. ioTra ...
Stocks Sink as Investors Worry About China’s A.I. Advances A jolt of panic hit technology stocks on Monday, with investors rattled by fears that A.I. advances by Chinese upstarts could threaten ...
Perth Zoo's last female elephant has left for her forever home in South Australia. Locals report seeing sparking and smoke near a power transmitter close to Arthur River, where a bushfire ripped ...
DeepSeek was tasked with selecting two stocks investors can buy now and hold long-term due to their growth potential.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback